SCHEMBL5041822

SCHEMBL5041822

O=C(c1ccc(Cl)cc1Cl)C(Br)c1ccc(Br)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 4/20 0.49
FLT4 P35916 4/20 0.49
KDR P35968 4/20 0.49
TSHR P16473 1/20 0.47
CASP1 P29466 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 3/20 0.44
MAPK1 P28482 1/20 0.44
HIF1A Q16665 1/20 0.44
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
GRIK1 P39086 1/20 0.40
ERCC5 P28715 1/20 0.40
FEN1 P39748 1/20 0.40
SRD5A2 P31213 1/20 0.40
CNR1 P21554 2/20 0.39
KMT2A Q03164 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5038563 0.92 TSHR (0.52) FLT1FLT4KDRTSHRCASP1
SCHEMBL1250577 0.86 SMN1; SMN2 (0.53) FLT1FLT4KDRTSHRCASP1
SCHEMBL11408672 0.78 TSHR (0.59) FLT1FLT4KDRTSHRCASP1
SCHEMBL11355953 0.78 FLT1 (0.46) FLT1FLT4KDRTSHRCASP1
SCHEMBL5319603 0.77 KMT2A (0.53) TSHRALDH1A1CNR1KMT2APOLB
SCHEMBL5334151 0.77 KMT2A (0.53) TSHRALDH1A1CNR1KMT2APOLB
SCHEMBL3377623 0.76 CES2 (0.47) FLT1FLT4KDRTSHRSMN1; SMN2
SCHEMBL10361369 0.75 TSHR (0.55) FLT1FLT4KDRTSHRCASP1
SCHEMBL1922201 0.75 SMN1; SMN2 (0.55) TSHRCASP1SMN1; SMN2ALDH1A1MAPK1
SCHEMBL11362277 0.75 FLT1 (0.43) FLT1FLT4KDRTSHRCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342032-B2 Thiazole derivatives having CB1-antagonistic, agonistic or partial agonistic activity SOLVAY PHARMACEUTICALS, INC. (NL) 2008-03-11 US disclosed
EP-1492779-A1 THIAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC, AGONISTIC OR PARTIAL AGONISTIC ACTIVITY Solvay Pharmaceuticals B.V. (NL) 2005-01-05 EP disclosed
US-20040266841-A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity ABBVIE B.V. (NL) 2004-12-30 US disclosed
WO-2003078413-A1 THIAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC, AGONISTIC OR PARTIAL AGONISTIC ACTIVITY SOLVAY PHARMACEUTICALS B.V. (NL) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266841-A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity CNR1, CNR2, CCKAR FLT1 1015/4885FLT4 1605/4885KDR 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.